|
|
靶向肿瘤相关巨噬细胞的抗肿瘤策略研究进展
|
Abstract:
肿瘤相关巨噬细胞(tumor associated macrophages, TAMs)是大多数肿瘤中浸润最多的一类免疫细胞，在肿瘤发生、发展和转移中均发挥关键性作用。TAMs具有较强的异质性与可塑性。受肿瘤微环境(Tumor Microenvironment, TME)复杂因子的影响，TAMs呈现不同的表型与功能，主要包括抑肿瘤的M1样TAMs和促肿瘤的M2样TAMs。大多数肿瘤中，TAMs呈现M2样表型，通过促进血管生成、抑制细胞毒性T细胞浸润和功能活化、诱导调节性T细胞、产生基质金属蛋白酶等机制抑制肿瘤免疫微环境，从而促进肿瘤的发生、发展和转移。因此，靶向TAMs已成为肿瘤免疫治疗的潜在重要手段。本文主要综述了目前已有的靶向TAMs的治疗策略和研究进展。
Tumor-associated macrophages (TAMs) are the most infiltrating class of immune cells in most tumors and play a key role in tumor development, progression and metastasis. TAMs have strong heterogeneity and plasticity. Influenced by the complex factors of tumor microenvironment (TME), TAMs present different phenotypes and functions, including M1-like TAMs that inhibit tumors and M2-like TAMs that promote tumors. In most tumors, TAMs present an M2-like phenotype and inhibit the tumor immune microenvironment by promoting angiogenesis, inhibiting cytotoxic T cell infiltration and functional activation, inducing regulatory T cells, and producing matrix metalloproteinases, thereby promoting tumor development, progression, and metastasis. Therefore, targeted TAMs have become a potentially important means of cancer immunotherapy. This review focuses on the existing therapeutic strategies and research progress of targeted Tams.
| [1] | Ceci, C., et al. (2020) Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel), 12, Article 3401.
https://doi.org/10.3390/cancers12113401 |
| [2] | Liu, Z., et al. (2019) Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells. Cell, 178, 1509- 1525e19. https://doi.org/10.1016/j.cell.2019.08.009 |
| [3] | Ginhoux, F., et al. (2010) Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science, 330, 841-845. https://doi.org/10.1126/science.1194637 |
| [4] | Guilliams, M., et al. (2013) Alveolar Macrophages Develop from Fetal Monocytes That Differentiate into Long-Lived Cells in the First Week of Life via GM-CSF. Journal of Experimental Medicine, 210, 1977-1992.
https://doi.org/10.1084/jem.20131199 |
| [5] | Bain, C.C., et al. (2014) Constant Replenishment from Circulating Monocytes Maintains the Macrophage Pool in the Intestine of Adult Mice. Nature Immunology, 15, 929-937. https://doi.org/10.1038/ni.2967 |
| [6] | Liu, Y. and Cao, X. (2015) The Origin and Function of Tumor-Associated Macrophages. Cellular & Molecular Immunology, 12, 1-4. https://doi.org/10.1038/cmi.2014.83 |
| [7] | Biswas, S.K. and Mantovani, A. (2010) Macrophage Plasticity and Interaction with Lymphocyte Subsets: Cancer as a Paradigm. Nature Immunology, 11, 889-896. https://doi.org/10.1038/ni.1937 |
| [8] | Bottazzi, B., et al. (1983) Regulation of the Macrophage Content of Neoplasms by Chemoattractants. Science, 220, 210-212. https://doi.org/10.1126/science.6828888 |
| [9] | Qian, B.Z. and Pollard, J.W. (2010) Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell, 141, 39-51.
https://doi.org/10.1016/j.cell.2010.03.014 |
| [10] | Hambardzumyan, D., Gutmann, D.H. and Kettenmann, H. (2016) The Role of Microglia and Macrophages in Glioma Maintenance and Progression. Nature Neuroscience, 19, 20-27. https://doi.org/10.1038/nn.4185 |
| [11] | Qian, B.Z., et al. (2011) CCL2 Recruits Inflammatory Monocytes to Facilitate Breast-Tumour Metastasis. Nature, 475, 222-225. https://doi.org/10.1038/nature10138 |
| [12] | Loyher, P.L., et al. (2018) Macrophages of Distinct Origins Contribute to Tumor Development in the Lung. Journal of Experimental Medicine, 215, 2536-2553. https://doi.org/10.1084/jem.20180534 |
| [13] | Zhu, Y., et al. (2017) Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 47, 323-338.e6.
https://doi.org/10.1016/j.immuni.2017.08.018 |
| [14] | Bowman, R.L., et al. (2016) Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 17, 2445-2459. https://doi.org/10.1016/j.celrep.2016.10.052 |
| [15] | Chen, Z., et al. (2017) Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Research, 77, 2266-2278. https://doi.org/10.1158/0008-5472.CAN-16-2310 |
| [16] | DeNardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 19, 369-382. https://doi.org/10.1038/s41577-019-0127-6 |
| [17] | Kumar, V., et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 44, 303-315.
https://doi.org/10.1016/j.immuni.2016.01.014 |
| [18] | Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61.
https://doi.org/10.1016/j.immuni.2014.06.010 |
| [19] | Pollard, J.W. (2009) Trophic Macrophages in Development and Disease. Nature Reviews Immunology, 9, 259-270.
https://doi.org/10.1038/nri2528 |
| [20] | Morandi, F. and Pistoia, V. (2014) Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 5, Article 394. https://doi.org/10.3389/fimmu.2014.00394 |
| [21] | Santarpia, M. and Karachaliou, N. (2015) Tumor Immune Microenvironment Characterization and Response to Anti-PD-1 Therapy. Cancer Biology & Medicine, 12, 74-78. |
| [22] | Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98-106. https://doi.org/10.1097/COC.0000000000000239 |
| [23] | Mellor, A.L., et al. (2002) Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses. The Journal of Immunology, 168, 3771-3776. https://doi.org/10.4049/jimmunol.168.8.3771 |
| [24] | Mbongue, J.C., et al. (2015) The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel), 3, 703-729. https://doi.org/10.3390/vaccines3030703 |
| [25] | Mantovani, A., et al. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. https://doi.org/10.1038/nature07205 |
| [26] | Cersosimo, F., et al. (2020) Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. International Journal of Molecular Sciences, 21, Article 5207. https://doi.org/10.3390/ijms21155207 |
| [27] | Mantovani, A. and Allavena, P. (2015) The Interaction of Anticancer Therapies with Tumor-Associated Macrophages. Journal of Experimental Medicine, 212, 435-445. https://doi.org/10.1084/jem.20150295 |
| [28] | Bonavita, E., et al. (2015) Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research, 128, 141-171. https://doi.org/10.1016/bs.acr.2015.04.013 |
| [29] | Leek, R.D., et al. (1996) Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma. Cancer Research, 56, 4625-4629. |
| [30] | Tian, Y., Ke, Y. and Ma, Y. (2020) High Expression of Stromal Signatures Correlated with Macrophage Infiltration, Angiogenesis and Poor Prognosis in Glioma Microenvironment. PeerJ, 8, e9038. https://doi.org/10.7717/peerj.9038 |
| [31] | Murdoch, C., et al. (2008) The Role of Myeloid Cells in the Promotion of Tumour Angiogenesis. Nature Reviews Cancer, 8, 618-631. https://doi.org/10.1038/nrc2444 |
| [32] | Su, B., et al. (2021) Let-7d Inhibits Intratumoral Macrophage M2 Polarization and Subsequent Tumor Angiogenesis by Targeting IL-13 and IL-10. Cancer Immunology, Immunotherapy, 70, 1619-1634.
https://doi.org/10.21203/rs.3.rs-27516/v1 |
| [33] | Smeester, B.A., et al. (2020) PLX3397 Treatment Inhibits Constitutive CSF1R-Induced Oncogenic ERK Signaling, Reduces Tumor Growth, and Metastatic Burden in Osteosarcoma. Bone, 136, Article ID: 115353.
https://doi.org/10.1016/j.bone.2020.115353 |
| [34] | Tap, W.D., et al. (2015) Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. The New England Journal of Medicine, 373, 428-437. https://doi.org/10.1056/NEJMoa1411366 |
| [35] | Molena, B., et al. (2011) Synovial Colony-Stimulating Factor-1 mRNA Expression in Diffuse Pigmented Villonodular Synovitis. Clinical and Experimental Rheumatology, 29, 547-550. |
| [36] | Ries, C.H., et al. (2014) Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 846-859. https://doi.org/10.1016/j.ccr.2014.05.016 |
| [37] | Butowski, N., et al. (2016) Orally Administered Colony Stimulating Factor 1 Receptor Inhibitor PLX3397 in Recurrent Glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium Phase II Study. Neuro-Oncology, 18, 557-564. https://doi.org/10.1093/neuonc/nov245 |
| [38] | von Tresckow, B., et al. (2015) An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research, 21, 1843-1850.
https://doi.org/10.1158/1078-0432.CCR-14-1845 |
| [39] | Pyonteck, S.M., et al. (2013) CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression. Nature Medicine, 19, 1264-1272. https://doi.org/10.1038/nm.3337 |
| [40] | Cassier, P.A., et al. (2015) CSF1R Inhibition with Emactuzumab in Locally Advanced Diffuse-Type Tenosynovial Giant Cell Tumours of the Soft Tissue: A Dose-Escalation And Dose-Expansion Phase 1 Study. The Lancet Oncology, 16, 949-956. https://doi.org/10.1016/S1470-2045(15)00132-1 |
| [41] | Piaggio, F., et al. (2016) A Novel Liposomal Clodronate Depletes Tumor-Associated Macrophages in Primary and Metastatic Melanoma: Anti-Angiogenic and Anti-Tumor Effects. The Journal of Controlled Release, 223, 165-177.
https://doi.org/10.1016/j.jconrel.2015.12.037 |
| [42] | Hiraoka, K., et al. (2008) Inhibition of Bone and Muscle Metastases of Lung Cancer Cells by a Decrease in the Number of Monocytes/Macrophages. Cancer Science, 99, 1595-1602. https://doi.org/10.1111/j.1349-7006.2008.00880.x |
| [43] | Gazzaniga, S., et al. (2007) Targeting Tumor-Associated Macrophages and Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. Journal of Investigative Dermatology, 127, 2031-2041.
https://doi.org/10.1038/sj.jid.5700827 |
| [44] | Zhou, Y., et al. (2020) Liposomal Clodronate Combined with Cisplatin or Sorafenib Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Suppressing FOXQ1 Expression. Cellular and Molecular Biology (Noisy-le-Grand), 66, 49-54. https://doi.org/10.14715/cmb/2019.66.1.8 |
| [45] | Zhang, W., et al. (2010) Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects. Clinical Cancer Research, 16, 3420-3430.
https://doi.org/10.1158/1078-0432.CCR-09-2904 |
| [46] | Cassetta, L. and Pollard, J.W. (2018) Targeting Macrophages: Therapeutic Approaches in Cancer. Nature Reviews Drug Discovery, 17, 887-904. https://doi.org/10.1038/nrd.2018.169 |
| [47] | Deshmane, S.L., et al. (2009) Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & Cytokine Research, 29, 313-326. https://doi.org/10.1089/jir.2008.0027 |
| [48] | Yoshimura, T. (2017) The Production of Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 in Tumor Microenvironments. Cytokine, 98, 71-78. https://doi.org/10.1016/j.cyto.2017.02.001 |
| [49] | Li, L., et al. (2018) High Levels of CCL2 or CCL4 in the Tumor Microenvironment Predict Unfavorable Survival in Lung Adenocarcinoma. Thoracic Cancer, 9, 775-784. https://doi.org/10.1111/1759-7714.12643 |
| [50] | De la Fuente Lopez, M., et al. (2018) The Relationship between Chemokines CCL2, CCL3, and CCL4 with the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer. Tumor Biology, 40.
https://doi.org/10.1177/1010428318810059 |
| [51] | Avila, M.A. and Berasain, C. (2019) Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box against Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 7, 293-294.
https://doi.org/10.1016/j.jcmgh.2018.11.002 |
| [52] | Zheng, Y., et al. (2021) Epigenetic Silencing of Chemokine CCL2 Represses Macrophage Infiltration to Potentiate Tumor Development in Small Cell Lung Cancer. Cancer Letters, 499, 148-163.
https://doi.org/10.1016/j.canlet.2020.11.034 |
| [53] | Steinberger, K.J., et al. (2020) Stress-Induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma. Cancer Prevention Research (Phila), 13, 747-760.
https://doi.org/10.1158/1940-6207.CAPR-19-0370 |
| [54] | Yao, M., et al. (2017) Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts. Translational Oncology, 10, 734-743.
https://doi.org/10.1016/j.tranon.2017.06.009 |
| [55] | Loberg, R.D., et al. (2007) CCL2 as an Important Mediator of Prostate Cancer Growth in Vivo through the Regulation of Macrophage Infiltration. Neoplasia, 9, 556-562. https://doi.org/10.1593/neo.07307 |
| [56] | Bonapace, L., et al. (2014) Cessation of CCL2 Inhibition Accelerates Breast Cancer Metastasis by Promoting Angiogenesis. Nature, 515, 130-133. https://doi.org/10.1038/nature13862 |
| [57] | Hitchcock, J.R. and Watson, C.J. (2015) Anti-CCL2: Building a Reservoir or Opening the Floodgates to Metastasis? Breast Cancer Research, 17, Article No. 68. https://doi.org/10.1186/s13058-015-0573-4 |
| [58] | Lebrecht, A., et al. (2004) Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer. Tumor Biology, 25, 14-17. https://doi.org/10.1159/000077718 |
| [59] | Loberg, R.D., et al. (2007) Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression in Vivo. Cancer Research, 67, 9417-9424. https://doi.org/10.1158/0008-5472.CAN-07-1286 |
| [60] | Moisan, F., et al. (2014) Enhancement of Paclitaxel and Carboplatin Therapies by CCL2 Blockade in Ovarian Cancers. Molecular Oncology, 8, 1231-1239. https://doi.org/10.1016/j.molonc.2014.03.016 |
| [61] | Nywening, T.M., et al. (2016) Targeting Tumour-Associated Macrophages with CCR2 Inhibition in Combination with FOLFIRINOX in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Finding, Non-Randomised, Phase 1b Trial. The Lancet Oncology, 17, 651-662.
https://doi.org/10.1016/S1470-2045(16)00078-4 |
| [62] | Chen, J., et al. (2017) SLAMF7 Is Critical for Phagocytosis of Haematopoietic Tumour Cells via Mac-1 Integrin. Nature, 544, 493-497. https://doi.org/10.1038/nature22076 |
| [63] | Xiao, Z., et al. (2015) Antibody Mediated Therapy Targeting CD47 Inhibits Tumor Progression of Hepatocellular Carcinoma. Cancer Letters, 360, 302-309. https://doi.org/10.1016/j.canlet.2015.02.036 |
| [64] | Edris, B., et al. (2012) Antibody Therapy Targeting the CD47 Protein Is Effective in a Model of Aggressive Metastatic Leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 109, 6656-6661.
https://doi.org/10.1073/pnas.1121629109 |
| [65] | Weiskopf, K., et al. (2016) CD47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small- Cell Lung Cancer. Journal of Clinical Investigation, 126, 2610-2620. https://doi.org/10.1172/JCI81603 |
| [66] | Liu, R., et al. (2017) CD47 Promotes Ovarian Cancer Progression by Inhibiting Macrophage Phagocytosis. Oncotarget, 8, 39021-39032. https://doi.org/10.18632/oncotarget.16547 |
| [67] | Wu, Z., et al. (2019) Identification of Glutaminyl Cyclase Isoenzyme isoQC as a Regulator of SIRPalpha-CD47 Axis. Cell Research, 29, 502-505. https://doi.org/10.1038/s41422-019-0177-0 |
| [68] | Logtenberg, M.E.W., et al. (2019) Glutaminyl Cyclase Is an Enzymatic Modifier of the CD47-SIRPalpha Axis and a Target for Cancer Immunotherapy. Nature Medicine, 25, 612-619. https://doi.org/10.1038/s41591-019-0356-z |
| [69] | Ansell, S.M., et al. (2021) Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 27, 2190-2199. |
| [70] | Petrova, P.S., et al. (2017) TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research, 23, 1068-1079.
https://doi.org/10.1158/1078-0432.CCR-16-1700 |
| [71] | Kaczanowska, S., Joseph, A.M. and Davila, E. (2013) TLR Agonists: Our Best Frenemy in Cancer Immunotherapy. Journal of Leukocyte Biology, 93, 847-863. https://doi.org/10.1189/jlb.1012501 |
| [72] | Le Mercier, I., et al. (2013) Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment. Cancer Research, 73, 4629-4640. https://doi.org/10.1158/0008-5472.CAN-12-3058 |
| [73] | Singh, M., et al. (2014) Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. The Journal of Immunology, 193, 4722-4731. https://doi.org/10.4049/jimmunol.1401160 |
| [74] | Vacchelli, E., et al. (2016) Trial Watch: Immunotherapy plus Radiation Therapy for Oncological Indications. Oncoimmunology, 5, e1214790. https://doi.org/10.1080/2162402X.2016.1214790 |
| [75] | Menzies, S., Mc Menamin, M. and Barry, R. (2017) Lentigo Maligna Successfully Treated with Combination Therapy of Topical Tazarotene and Imiquimod. Clinical and Experimental Dermatology, 42, 468-470.
https://doi.org/10.1111/ced.13053 |
| [76] | Klichinsky, M., et al. (2020) Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nature Biotechnology, 38, 947-953. https://doi.org/10.1038/s41587-020-0462-y |
| [77] | Zhang, L., et al. (2020) Pluripotent Stem Cell-Derived CAR-Macrophage Cells with Antigen-Dependent Anti-Cancer Cell Functions. Journal of Hematology & Oncology, 13, Article No. 153. https://doi.org/10.1186/s13045-020-00983-2 |
| [78] | Hirsch, E., et al. (2000) Central Role for G Protein-Coupled Phosphoinositide 3-Kinase Gamma in Inflammation. Science, 287, 1049-1053. https://doi.org/10.1126/science.287.5455.1049 |
| [79] | Kaneda, M.M., et al. (2016) PI3Kgamma Is a Molecular Switch That Controls Immune Suppression. Nature, 539, 437-442. https://doi.org/10.1038/nature19834 |
